A USEFUL TOOL FOR EVALUATING THE FEAR OF INJECTING AND SELF-TESTING IN DIABETIC PATIENTS- THE SPANISH VERSION OF THE DIABETES FEAR OF INJECTING AND SELF-TESTING QUESTIONNAIRE (D-FISQ)
Author(s)
Pablo Rebollo, MD, PhD, Scientific Director1, Paloma González, PhD, Outcomes Research Manager2, Pilar Baillo, MD, Family Doctor3, Félix Laporta, MD, Family Doctor4, Joan Martorell, MD, Family Doctor5, Joaquín Morís, PhD, project manager1, Javier Rejas, MD, Outcomes Research Manager21BAP Health Outcomes, Oviedo, Asturias, Spain; 2 Pfizer Spain, Alcobendas, Madrid, Spain; 3 C.A.P. Cervera, Cervera, Lleida, Spain; 4 C.S. La Roda, La Roda, Albacete, Spain; 5 C.A.P. Guissona, Guissona, Lleida, Spain
OBJECTIVE: To validate into Spanish and recalibrate the D-FISQ, a 30-items 2-dimensions [Fear of self-injecting (FSI) and self-testing (FST)], specific questionnaire for evaluating the fear of injecting and self-testing in diabetic patients. METHODS: Forward-backward translations in duplicate were carried out by professional translators and revised by expert and non-expert panels. Type 1 and 2 diabetic patients, both genders above 18 years were enrolled in 3 primary care centres. Spanish D-FISQ (in duplicate 15-days separated to assess test-retest reliability), trait-anxiety scale of the STAI and eight specific questions about glycemic control, compliance and pain were administered. Sociodemographic and clinical data were also collected. Feasibility (item and questionnaire responder rate and time to completion) content validity (item-total correlation and factor analysis), concept validity (correlation with STAI and specific questions) and reliability (test-retest and Cronbach's Alpha) were assessed. RESULTS: A 32-items version was developed by an expert panel and administered to 93 (35 Type 1, 58 Type 2) insulin-treated diabetic patients. Ninety-nine% of patients answered all items in 5 minutes (median). Item-total correlation and factor analysis lead to an abridged version with 19 items, maintaining the two original dimensions, and explaining the 47.4% of total variance: FSI; 29.5%, and FST;17.9%. Test-retest correlation coefficient were 0.85 (FSI) and 0.94 (FST); Cronbachxs Alpha were 0.81 (FSI) and 0.89 (FST). FST correlated positively with time treated with insulin (p<0.011, type 2); FSI correlated positively with patient reported compliance (p=0.002) and lack of worry in diabetes consequences (p=0.005, type 2), and negatively with time treated with insulin (p<0.023, type 1). CONCLUSIONS. We developed a new-recalibrated version of the Spanish D-FISQ called MIAT-D. Feasibility, dimensionality, content validity and reliability were accurate. Due to the fact of cultural differences and lack of a gold standard for concept validity, this property need to be explored in further studies.
Conference/Value in Health Info
2006-10, ISPOR Europe 2006, Copenhagen, Denmark
Value in Health, Vol. 9, No.6 (November/December 2006)
Code
PDB47
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Diabetes/Endocrine/Metabolic Disorders
Explore Related HEOR by Topic